Register entry
BioCryst Pharmaceuticals, Inc.
- Registered sites
- 0
- Drug products
- 6
- Live patents
- 194
- Countries
- 0
- Base
- Unknown
Sites
Facilities
0No registered facilities
This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.
Exclusivity
Patents
194Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| ORLADEYO | BEROTRALSTAT DIHYDROCHLORIDE | Mar 2035 |
| ORLADEYO | BEROTRALSTAT DIHYDROCHLORIDE | Apr 2035 |
| ORLADEYO | BEROTRALSTAT DIHYDROCHLORIDE | Sept 2035 |
| ORLADEYO | BEROTRALSTAT DIHYDROCHLORIDE | Oct 2035 |
| ORLADEYO | BEROTRALSTAT DIHYDROCHLORIDE | Nov 2039 |
| ORLADEYO | BEROTRALSTAT DIHYDROCHLORIDE | May 2040 |
| RAPIVAB | PERAMIVIR | Feb 2027 |
| RAPIVAB | PERAMIVIR | May 2027 |
Catalogue
Marketed products
6Showing 6 of 6.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| Orladeyo | Berotralstat hydrochloride | CAPSULE | NDA |
| Orladeyo | Berotralstat hydrochloride | CAPSULE | NDA |
| Orladeyo | Berotralstat hydrochloride | PELLET | NDA |
| Orladeyo | Berotralstat hydrochloride | PELLET | NDA |
| Orladeyo | Berotralstat hydrochloride | PELLET | NDA |
| Orladeyo | Berotralstat hydrochloride | PELLET | NDA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.